Clinical Collaborations & Partnerships

Oncoceutics has active collaborations with a number of leading cancer institutions. These institutions have validated the efficacy and safety of ONC201 in a variety of preclinical studies, and several institutions are now working with the company to explore the efficacy of ONC201 in clinical trials.

Rutgers Cancer Institute of New Jersey

Phase I – Solid Tumors (NCT02250781)
The first clinical trial of ONC201 began in January 2015 at Rutgers Cancer Institute of New Jersey. The trial, identified as NCT02250781 on www.clinicaltrials.gov, is entitled “Oral ONC201 in Treating Patients with Advanced Solid Tumors.” The Phase I trial is investigating the use of ONC201 in patients with solid tumors not amenable to treatment with standard chemotherapy. The trial is being led by Mark Stein, MD, a medical oncologist and member of the Phase I/Investigational Therapeutics Program at the Cancer Institute of New Jersey. Dose escalation and expansion cohorts have been completed, treating a total of 28 patients. Subsequent to the completion of the expansion cohort, a dose intensification cohort has been initiated and is enrolling patients on a weekly dosing schedule.

MD Anderson Cancer Center

Phase I/II – Leukemia (NCT02392572)
Phase I/II – Lymphoma (NCT02420795)
Under a strategic alliance and research collaboration agreement for the clinical development of ONC201, The University of Texas MD Anderson Cancer Center announced the initiation of two clinical trials in January 2015.  The strategic alliance provides for a sharing of risk and potential commercialization of ONC201 and is expected to enroll approximately 50 patients with acute leukemias and 50 patients with non-Hodgkin lymphomas.  The first trial, identified as NCT02392572 on www.clinicaltrials.gov, is entitled “Phase I/II Study of Oral ONC201 in Patients with Relapsed/Refractory Acute Leukemias and High-Risk Myelodysplastic Syndromes.” The Phase I/II trial is investigating the use of ONC201 in patients with relapsed or refractory acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and myelodysplastic syndrome (MDS).  Gautam Borthakur, MD, Associate Professor in the Department of Leukemia at MD Anderson Cancer Center, is the Principal Investigator for the trial.  The second trial, identified as NCT02420795 on www.clinicaltrials.gov, is entitled “Study of Oral ONC201 in Patients With Relapsed/Refractory Non-Hodgkin’s Lymphoma.”  The Phase I/II trial is investigating the use of ONC201 in patients with relapsed or refractory mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL) and transformed large cell lymphoma (TLCL). Michael Wang, MD, Professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center, is the Principal Investigator for the trial.

Massachusetts General Hospital / Dana Farber Cancer Institute

Phase II – GBM (NCT02525692)
With support from an Small Business Innovation Research (SBIR) grant from the National Institutes of Health awarded to Oncoceutics in 2015, the company has initiated a Phase II clinical trial investigating the use of ONC201 in patients with relapsed or refractory glioblastoma multiforme (GBM). Isabel Arrillaga-Romany, MD, PhD, Associate Clinical Director of Neuro-Oncology at Massachusetts General Hospital, and Patrick Wen, MD, Director of the Center for Neuro-Oncology at the Dana Farber Cancer Institute, are the Principal Investigators for the trial.

Fox Chase Cancer Center

Phase I – Solid Tumors and Multiple Myeloma (NCT02609230)
This clinical trial is evaluating the safety and pharmacodynamics of different ONC201 administration schedules in patients with advanced solid tumors or multiple myeloma. Anthony Olszanski, MD, Director of Clinical Drug Development at Fox Chase Cancer Center, is the Principal Investigator for the trial.

Phase II– Multiple Myeloma (NCT02863991)
This clinical trial is evaluating ONC201 in patients with relapsed/refractory multiple myeloma. Henry Fund, MD, Vice-Chair, Department of Hematology/Oncology, is the Principal Investigator for the trial.

Expanded Access

Expanded Access – Recurrent Histone H3 Mutant Glioma (NCT03134131)

The objective of this expanded access program is to provide ONC201 on a single patient compassionate use basis to eligible adult subjects with recurrent glioma that exhibits a missense histone H3 mutation .